Primary mediastinal/thymic diffuse large B-cell lymphoma: a population-based study on incidence and survival.

Ann Hematol

Division of Medical Oncology, Cancer Center and State Key Laboratory of Biotherapy, Sichuan University West China Hospital, Chengdu, China.

Published: July 2023

Primary mediastinal large B-cell lymphoma is a rare subtype of lymphoma. The contemporary incidence of primary mediastinal large B-cell lymphoma remains unknown, and a large population-based study has not been reported. It is essential to provide guidance for further strategies in reducing the disease burden via population-based preventive initiatives. This study aims to explore the epidemiology and effect of therapeutic advances on the survival of patients with primary mediastinal large B-cell lymphoma. This population-based study was conducted using the Surveillance, Epidemiology, and End Results Program (SEER), covering the period from 1975 to 2018. A total of 774 patients in the SEER 9 and 1654 patients in the SEER 18 were analyzed. The age-adjusted incidence rate of primary mediastinal large B-cell lymphoma increased from 0.05/1,000,000 in 1975 to 2.38/1,000,000 in 2018. A significant positive linear increase in the incidence trend was found in primary mediastinal large B-cell lymphoma, with an annual percent change of 8.47% (95% confidence interval 7.7-9.2%, P < 0.001, z test). The survival in primary mediastinal large B-cell lymphoma was significantly superior to nodal diffuse large B-cell lymphoma. The incidence of PMBCL increases over the year. The survival of patients with primary mediastinal large B-cell lymphoma has improved over time.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-023-05225-2DOI Listing

Publication Analysis

Top Keywords

large b-cell
36
b-cell lymphoma
36
primary mediastinal
28
mediastinal large
28
population-based study
12
large
10
lymphoma
10
b-cell
9
primary
8
diffuse large
8

Similar Publications

High-grade-B-cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements (double hit [HGBL-DH] or triple hit [HGBL-TH]), or not otherwise specified (HGBL-NOS), are considered to be more aggressive diseases among large B-cell lymphomas (LBCL). CD19-targeting Chimeric Antigen Receptor (CAR) T-cells have changed the prognosis of chemoresistant LBCL. Clinical and pathological data of patients treated for relapsed/refractory LBCL or HGBL in third line or more, all characterized by FISH, were collected from the French DESCAR-T registry.

View Article and Find Full Text PDF

Objectives: To investigate the factors affecting laboratory data and computed tomography (CT) attenuation values of L1 trabecular and femoral bone marrow, potential markers for differentiating between adult-onset Still's disease and intravascular large B-cell lymphoma.

Methods: We conducted a retrospective observational study on patients diagnosed with adult-onset Still's disease or intravascular large B-cell lymphoma. Clinical and laboratory data, and CT attenuation values of the bone marrow were compared.

View Article and Find Full Text PDF

Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous metastatic lymphoma that can be treated by targeting angiogenesis. Apolipoprotein C1 (APOC1) plays a significant role in the proliferation and metastasis of various malignant tumors; however, its role in DLBCL-particularly its effects on angiogenesis-remains largely unexplored. This study investigates the correlation between APOC1 expression and patient prognosis in DLBCL.

View Article and Find Full Text PDF

Background: T/histiocyte-rich large B-cell lymphoma (T/HRBCL) is a highly aggressive subtype of diffuse large B-cell lymphoma characterized histologically by the presence of a few neoplastic large B cells amidst an abundant background of reactive T lymphocytes and/or histiocytes. T/HRBCL commonly affects the lymph nodes, followed by extranodal sites, such as the spleen, liver, and bone marrow, with rare occurrences in the gastrointestinal tract. Primary gastrointestinal T/HRBCL lacks specific clinical and endoscopic manifestations, and it is difficult to differentiate from inflammatory diseases, nodular lymphocyte predominant Hodgkin lymphoma, and other diseases on a histological basis, thereby hindering early diagnosis.

View Article and Find Full Text PDF

Intravascular large B-cell lymphoma (IVLBL) poses a diagnostic challenge due to its varied, nonspecific symptoms. Utilizing PET-CT can be valuable in identifying lesions across the body, aiding clinicians in targeted biopsy planning. Clinicians need to be aware that IVLBL may manifest hepatic lesions along Glisson's sheath mimicking intrahepatic cholangiocarcinoma.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!